THE UTILITY OF CLOUD COMPUTING.
- Published in:
- Bio-IT World, 2011, v. 10, n. 6, p. 32
- By:
- Publication type:
- Article
Works matching DE "AMYLIN Pharmaceuticals Inc."
Results: 23
1
2
Amylin, Amazon, and the Cloud.
- Published in:
- Bio-IT World, 2009, v. 8, n. 6, p. 35
- By:
- Publication type:
- Article
3
Biomedical briefing.
- Published in:
- Nature Medicine, 2012, v. 18, n. 8, p. 1162, doi. 10.1038/nm0812-1162
- Publication type:
- Article
4
Drugs in traffic: the road to approval.
- Published in:
- Nature Medicine, 2011, v. 17, n. 12, p. 1542, doi. 10.1038/nm1211-1542
- Publication type:
- Article
5
Class of once-weekly diabetes drugs poised for approval.
- Published in:
- Nature Medicine, 2011, v. 17, n. 12, p. 1528, doi. 10.1038/nm1211-1528b
- By:
- Publication type:
- Article
6
New drug and biologic product approvals, 2005.
- Published in:
- American Journal of Health-System Pharmacy, 2006, v. 63, n. 4, p. 304, doi. 10.2146/news050052
- By:
- Publication type:
- Article
7
Business digest.
- Published in:
- Chemistry & Industry, 2012, v. 76, n. 8, p. 20, doi. 10.1002/cind.7608_4.x
- Publication type:
- Article
8
Science in brief.
- Published in:
- Chemistry & Industry, 2009, n. 19, p. 10
- Publication type:
- Article
9
Science briefs.
- Published in:
- Chemistry & Industry, 2004, n. 15, p. 9
- Publication type:
- Article
10
Amylin's $1 billion heavyweight deal.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 2, p. 109, doi. 10.1038/nbt0210-109
- By:
- Publication type:
- Article
11
Deaths stalk GLP-1 agonist.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 11, p. 1204, doi. 10.1038/nbt1108-1204b
- By:
- Publication type:
- Article
12
People.
- Published in:
- Nature Biotechnology, 2003, v. 21, n. 12, p. 1521, doi. 10.1038/nbt1203-1521
- Publication type:
- Article
13
Good news for Amylin.
- Published in:
- Nature Biotechnology, 1999, v. 17, n. 10, p. 940, doi. 10.1038/13602
- By:
- Publication type:
- Article
14
Exenatide: AC 2993, AC002993, AC2993A, Exendin 4, LY2148568.
- Published in:
- Drugs in R&D, 2004, v. 5, n. 1, p. 35
- By:
- Publication type:
- Article
15
Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss Through 4 Years.
- Published in:
- MD Conference Express, 2012, p. 13, doi. 10.1177/155989771216004
- By:
- Publication type:
- Article
16
US FDA approves exenatide extended-release for the treatment of Type 2 diabetes.
- Published in:
- Expert Review of Endocrinology & Metabolism, 2012, v. 7, n. 2, p. 136
- By:
- Publication type:
- Article
17
THE SPIRIT OF BLASIUS: SANDRIDGE AS AN ANTIDOTE TO THE POISON PUT.
- Published in:
- Columbia Law Review, 2015, v. 115, n. 2, p. 375
- By:
- Publication type:
- Article
18
"If You Poison Us Do We Not Die?"--A Critical Analysis of the Legality of Poison Puts in the Wake of San Antonio Fire & Police Pension Fund v. Amylin, Inc.
- Published in:
- Brigham Young University Law Review, 2010, v. 2010, n. 2, p. 767
- By:
- Publication type:
- Article
19
Meeting Reporter.
- Published in:
- Patient Care (Print), 2004, v. 38, n. 8, p. 12
- Publication type:
- Article
20
News and Views.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 3, p. 288, doi. 10.1111/j.1463-1326.2012.01578.x
- By:
- Publication type:
- Article
21
San Diego survives Amylin shock.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 6, p. 475, doi. 10.1038/nbt0613-475
- By:
- Publication type:
- Article
22
Amylin's three-party good-bye.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 9, p. 812, doi. 10.1038/nbt0912-812a
- By:
- Publication type:
- Article
23
Amylin's $7 billion GLP-1 deal.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 8, p. 730, doi. 10.1038/nbt0812-730a
- By:
- Publication type:
- Article